ADM, a global leader in innovative solutions from nature, has announced findings from a recent clinical study on the effects of PRIOME®MH, a postbiotic derived from Bifidobacterium animalis subsp. lactis CECT 8145, in adult dogs. The study revealed that the postbiotic supports healthy blood sugar levels, with a significant reduction in postprandial blood glucose levels observed after a normal kibble meal compared to a placebo, particularly during a weight loss phase. Additionally, lower levels of gamma-glutamyl transferase, a liver function marker, were noted during a weight gain phase. The results suggest a potential role for PRIOME®MH in supporting canine metabolic health, contributing to the growing interest in functional pet nutrition.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。